MX2022006631A - Dosificacion de un inhibidor de la tirosina cinasa de bruton. - Google Patents

Dosificacion de un inhibidor de la tirosina cinasa de bruton.

Info

Publication number
MX2022006631A
MX2022006631A MX2022006631A MX2022006631A MX2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A
Authority
MX
Mexico
Prior art keywords
bruton
dosing
tyrosine kinase
kinase inhibitor
methoxybenzamido
Prior art date
Application number
MX2022006631A
Other languages
English (en)
Spanish (es)
Inventor
Nisha Nanda
Donald Tsai
Barbara Jean Brandhuber
Nora Chien Yee Ku
Steven August Smith
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MX2022006631A publication Critical patent/MX2022006631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022006631A 2019-12-06 2020-12-03 Dosificacion de un inhibidor de la tirosina cinasa de bruton. MX2022006631A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962944674P 2019-12-06 2019-12-06
US202063077996P 2020-09-14 2020-09-14
US202063109698P 2020-11-04 2020-11-04
PCT/US2020/063089 WO2021113497A1 (en) 2019-12-06 2020-12-03 Dosing of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2022006631A true MX2022006631A (es) 2022-09-07

Family

ID=73854977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006631A MX2022006631A (es) 2019-12-06 2020-12-03 Dosificacion de un inhibidor de la tirosina cinasa de bruton.

Country Status (10)

Country Link
US (1) US12551463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069219A1 (cg-RX-API-DMAC7.html)
JP (3) JP7142173B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220100992A (cg-RX-API-DMAC7.html)
CN (1) CN115175677A (cg-RX-API-DMAC7.html)
AU (2) AU2020397034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009716A2 (cg-RX-API-DMAC7.html)
IL (1) IL292882B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006631A (cg-RX-API-DMAC7.html)
WO (1) WO2021113497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN114605327B (zh) * 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Also Published As

Publication number Publication date
EP4069219A1 (en) 2022-10-12
KR20230127372A (ko) 2023-08-31
CN115175677A (zh) 2022-10-11
AU2024201263B2 (en) 2025-05-01
JP2022177119A (ja) 2022-11-30
IL292882B1 (en) 2026-05-01
US12551463B2 (en) 2026-02-17
AU2020397034A1 (en) 2022-07-21
AU2024201263A1 (en) 2024-03-14
BR112022009716A2 (pt) 2022-08-09
IL292882A (en) 2022-07-01
JP2025098099A (ja) 2025-07-01
NZ788615A (en) 2024-10-25
CA3160417A1 (en) 2021-06-10
US20230041515A1 (en) 2023-02-09
AU2020397034B2 (en) 2023-12-07
JP7142173B2 (ja) 2022-09-26
JP7654604B2 (ja) 2025-04-01
KR20220100992A (ko) 2022-07-18
WO2021113497A1 (en) 2021-06-10
JP2022518974A (ja) 2022-03-17

Similar Documents

Publication Publication Date Title
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
MX386113B (es) Polimorfos de n-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[(2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamida y sales de los mismos.
EA202092154A1 (ru) Комбинированная терапия
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
MX2023001468A (es) Tratamiento de cancer de prostata.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2018014577A (es) Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
TN2017000158A1 (en) Carbazole derivatives
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
ZA202101118B (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
MX2021013602A (es) Inhibidores de jak.
LT3972604T (lt) Brutono tirozino kinazės inhibitorius, skirtas naudoti lėtinės spontaninės dilgėlinės gydymui
BR112022009716A2 (pt) Dosagem de um inibidor de tirosina quinase de bruton
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
MX2021005936A (es) Metodos farmaceuticos.
MX2022001159A (es) Nueva formulacion farmaceutica.
PL1631291T3 (pl) Zastosowanie inhibitorów kinazy tyrozynowej do leczenia cukrzycy
WO2020232330A8 (en) Inhibiting agents for bruton's tyrosine kinase
EA201990843A1 (ru) Лечение рака предстательной железы
CY1125534T1 (el) Ενωσεις χρησιμες για την αναστολη της cdk7
EA202190270A1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина
PL426157A1 (pl) Zastosowanie medyczne 4-(2-fluorofenylo)-1-(4-metyloimidazol-5-ilo)tiosemikarbazydu